Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GeparPiPPa: neoadjuvant endocrine therapy with trastuzumab, pertuzumab ± inavolisib in HER2-positive, HR-positive, PIK3CA-mutant early breast cancer
2021-002323-38Phase 2Active
- Sponsor
- GBG Forschungs
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of inavolisib in breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoint: Pathological complete response (ypT0/is ypN0). Started Feb 2022; status: active.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2021-002323-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002323-38.